Pasireotide in tumor diagnosis and treatment by translational medicine
10.3760/cma.j.issn.1673-422X.2013.05.008
- VernacularTitle:帕瑞泰在肿瘤诊疗中的转化医学研究
- Author:
Hua ZHU
;
Nina ZHOU
;
Feng WANG
;
Zhi YANG
- Publication Type:Journal Article
- Keywords:
Receptors,somatostatin;
Nuclear medicine;
Translational medicine;
Pasireotide
- From:
Journal of International Oncology
2013;(5):345-347
- CountryChina
- Language:Chinese
-
Abstract:
The somatostatin analogue pasireotide is a new type of protein which is the first therapeutic agent targeted to the pituitary.Pasireotide can prevent adrenocorticotropic hormone release and inhibit the growth of tumor cells after coupling with somatostatin receptor of the target cell membranes.Pasireotide has a high binding affinity for most of somatostatin receptor (SSTR) subtypes and in particular for SSTR5.Pasireotide can paly an important role in the new round of new targets for individualized diagnosis and treatment of tumors through the studies of translational medicine.
